Can adding radiation to immunotherapy and chemotherapy boost breast cancer treatment?
NCT ID NCT07276880
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether adding low or high dose radiation to standard chemotherapy and the immunotherapy drug pembrolizumab can improve treatment for people with node-positive triple negative breast cancer. Thirty-two participants will be randomly assigned to receive either low or high dose radiation to the breast tumor before surgery. The main goal is to see which dose leads to a higher rate of complete cancer clearance in the lymph nodes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pembrolizumab (immunotherapy drug) and radiation therapy
What this could lead to
If successful, this could help determine the best radiation dose to boost the immune system's response against triple negative breast cancer when combined with immunotherapy and chemotherapy.
What could go wrong
This is a small, early-phase trial with only 32 participants, so results may not apply to all patients. The added radiation could increase side effects, and it's unclear if it will improve outcomes over standard treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of North Carolina
RECRUITINGChapel Hill, North Carolina, 27599, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••